PaxVax appoints COO Farzan as president; Immunovaccine gets green light for RSV vaccine trial;

> PaxVax has appointed COO Nima Farzan as company president and COO. Release

> Takeda's vaccines president Rajeev Venkayya says his company is evaluating potential candidates in its pipeline that might have an impact on the Ebola virus. Interview

> Health Canada has cleared Immunovaccine to begin a Phase I trial of its RSV vaccine candidate. Release

> Two patients have been on Aduro Biotech's cancer vaccine combo regimen for more than two years and have snown no evidence of cumulative toxicity. Release

Half of girls ages 11-12, the age the CDC recommends, receive the HPV vaccine. Report

And Finally... A new study confirms long-held speculation that anti-vaccine sentiment can concentrate in communities, increasing the risk of outbreaks. Report

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.